Lyka Lab shares jumped more than 6% in morning trade after the company received CDSCO approval to manufacture and market Pregabalin Gel 8% w/w in India.
This topical treatment, targeted at reducing Diabetic Neuropathic Pain (DNP), represents a significant advancement in the management of diabetes-related neuropathy in India, where diabetes has risen dramatically.
Clinical trials demonstrated that it is both effective and well-tolerated, with fewer effects than oral pregabalin.
As of 9:16 am, Lyka Lab shares were trading 5.75% higher at Rs 158.19 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
